title: Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging.
abstract: Many years after therapeutic wilderness, sorafenib finally showed a clinical benefit in patients with advanced hepatocellular carcinoma. After the primary general enthusiasm worldwide, some disappointments emerged particularly since no new treatment could exceed or at least match sorafenib in this setting. Without these new drugs, research focused on optimizing care of patients treated with sorafenib. One challenging research approach deals with identifying prognostic and predictive biomarkers of sorafenib in this population. The task still seems difficult; however appropriate investigations could resolve this dilemma, as observed for some malignancies where other drugs were used.
authors.affiliation: Mohamed Bouattour, Audrey Payancé, Department of Hepatology, Beaujon University Hospital (AP-HP - Paris 7 Diderot), 92110 Clichy, France.
authors.forename: Mohamed
authors.initials: M
authors.lastname: Bouattour
authors.affiliation: Mohamed Bouattour, Audrey Payancé, Department of Hepatology, Beaujon University Hospital (AP-HP - Paris 7 Diderot), 92110 Clichy, France.
authors.forename: Audrey
authors.initials: A
authors.lastname: Payancé
authors.affiliation: Mohamed Bouattour, Audrey Payancé, Department of Hepatology, Beaujon University Hospital (AP-HP - Paris 7 Diderot), 92110 Clichy, France.
authors.forename: Johanna
authors.initials: J
authors.lastname: Wassermann
keywords: Antiangiogenic therapies; Functional imaging; Hepatocellular carcinoma; Predictive biomarkers; Prognosis biomarkers; Sorafenib